SZSeyed Sina Zakavi

Seyed Sina Zakavi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seyed Sina Zakavi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High‐Intensity Focused Ultrasound in Treatment of Primary Breast Cancer: A Systematic Review and Meta‐Analysis

    by Sogol Alikarami, Hamid Harandi, Ali Jahanshahi, Seyed Sina Zakavi, Negin Frounchi, Mohammad Ghavam, Sara Momtazmanesh

    Background: In recent years, tumor management strategies have focused on less invasive methods, aiming to yield optimal efficacy while minimizing further complications and enhancing the overall outcome of patients. High‐intensity focused ultrasound (HIFU), a known thermal ablative technique, has shown promising results in breast cancer treatment. Therefore, we performed this systematic review and meta‐analysis to assess the clinical, histopathologic, immunologic, and radiologic outcomes of HIFU ablative therapy and its complications in patients with primary breast cancer. Methods: We searched PubMed and Scopus databases to identify the eligible articles. Data extraction was conducted by two independent authors. A random effects model was employed to pool the proportion of remaining tumor after HIFU therapy in breast cancer. A subgroup analysis was performed according to imaging guidance modality and study design. Moreover, the heterogeneity and bias were assessed using funnel plot, Egger's regression plot, and Baujat plot. Pooled CD4/CD8 ratio mean difference between HIFU and radical mastectomy was measured using a fixed‐effect model. Results: We included 26 studies and 677 participants in the systematic review. Tumor necrosis rates varied, with 4 studies reporting less than 50% complete necrosis and 5 more than 50%. Two studies observed HIFU‐induced disturbances in the microvasculature of the targeted tissue. Six noted no contrast enhancement in successfully treated areas, two observed a thin rim indicating necrosis or fibrosis, and four reported a persistent enhancement in MRI images associated with a residual viable tumor. The weighted proportion of patients with residual tumor was 0.59 (95% CI; 0.44–0.73). The subgroup analysis demonstrated that although the pooled proportion of ultrasound‐guided studies was notably higher than magnetic resonance imaging‐guided studies (0.71 vs. 0.57), the between‐group difference was not statistically significant ( p = 0.1693). The diagnostic tools showed that the results are driven by certain studies, and there is also a potential small‐study effect. Furthermore, the CD4/CD8 ratio was higher in the HIFU group, with a weighted mean difference of 0.6 (95% CI: 0.41–0.78). The most prevalent side effects were pain (47.14%) and skin burn (2.59%). Conclusions: HIFU is a relatively safe procedure for the treatment of breast cancer as an independent or conjugated therapy and its effectiveness is promising regarding histopathological response, immunological reactivity, and vascular damage in the targeted area.


  • Open Access

    Can Gamma-glutamyl Transferase Predict Unhealthy Metabolic Phenotypes Among Healthcare Workers in Azar Cohort Study?

    by Mohammadhossein Somi, Seyed Sina Zakavi, Alireza Ostadrahimi, Negin Frounchi, Neda Gilani, Sarvin Sanaie, Elnaz Faramarzi

    Background: Although various studies have assessed the correlation between gamma-glutamyl transferase (GGT) and cardiometabolic risk factors in obesity, no research has differentiated among metabolically-healthy obese (MHO) and metabolically unhealthy obese (MUHO), metabolically-healthy lean (MHL), and metabolically-unhealthy lean (MUHL). Objectives: Accordingly, this study evaluated the correlation between GGT and cardiometabolic phenotypes among healthcare workers. Methods: In this study, there were anthropometric measurements as well as the measurements of fasting blood sugar (FBS), GGT, cholesterol, triglyceride (TG), high lipoprotein density (HDL), and blood pressure in 1458 healthcare workers enrolled in the Azar Cohort Study. Metabolic syndrome (MetS) was defined according to the National Cholesterol Education Program Adult Treatment Panel III (ATP III). Accordingly, the participants were divided into four cardiometabolic phenotypes. Results: In this cross-sectional study, there was a significant difference in the prevalence of cardiometabolic phenotypes regarding the GGT tertiles (P ≤ 0.001). The highest prevalence of MHO was observed in the third GGT tertile. The mean waist circumference, TG, FBS, HDL, and systolic and diastolic blood pressure levels increased in the MHO, MUHO, and MHL groups in a dose dependent manner with an increase in the GGT tertiles (P < 0.05). In comparing the highest and lowest GGT tertile, the risk of MHO and MUHO increased by 2.84 (95%CI 2.01 - 4.01) and 9.12 (95%CI 5.54 - 15), respectively. However, the correlation between the GGT tertile and MUHL did not reveal a similar trend. The ROC curve shows the cutoff value of 18.5 U/L for GGT, which allowed us to distinguish between the MUHO and MHO individuals. Conclusions: The findings revealed that GGT can indicate the risk of MetS as such, it can be used to detect at-risk MHO individuals and administer proper interventions.